CCRP Initiative: Countermeasures Against Chemical Threats (CounterACT) Therapeutics Discovery and Early-Stage Development (UG3/UH3 Clinical Trial Not Allowed)
ID: 341905Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $350K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/341905

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-22-209.html
Timeline
    Description

    The National Institutes of Health (NIH) has announced a funding opportunity under the Countermeasures Against Chemical Threats (CounterACT) initiative, aimed at supporting the early-stage development of therapeutics to mitigate the adverse health effects of toxic chemical exposure. This initiative seeks applications for projects that validate therapeutic targets and characterize lead compounds, ultimately delivering a well-characterized therapeutic candidate that improves upon existing standards of care for chemical exposure treatment. The funding is particularly relevant in the context of potential mass casualty situations involving chemical threats, as identified by the Department of Homeland Security. Interested applicants can apply for a cooperative agreement with an award ceiling of $350,000, and the application deadline is set for October 17, 2024. For further inquiries, applicants may contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov.

    Point(s) of Contact
    OERWebmaster03@od.nih.gov
    Files
    Title
    Posted
    PAR-22-209-Full-Announcement.html
    PAR-22-209.html
    The Department of Health and Human Services has issued a Funding Opportunity Announcement (FOA) under the Countermeasures Against Chemical Threats (CounterACT) initiative, focusing on the early-stage development of therapeutics to address toxic chemical exposure effects. The NIH's National Institute of Neurological Disorders and Stroke (NINDS) and other affiliated institutes will support projects that aim to develop medical countermeasures (MCMs) applicable in mass casualty situations involving chemical threats identified by the Department of Homeland Security. The UG3/UH3 cooperative agreement mechanism allows research teams to validate therapeutic targets, optimize candidate compounds, and demonstrate efficacy, all while adhering to regulatory and biosafety guidelines. Applications must demonstrate strong preliminary data supporting their approaches, detail annual milestones for project progress, and ensure safety compliance while working with hazardous chemicals. The total project period can extend up to five years, with specific budgetary limits for each phase, necessitating careful planning for scientific rigor and institutional collaboration. Successful projects are expected to deliver a characterized therapeutic candidate that improves upon existing standards of care for chemical exposure treatment.
    Similar Opportunities
    CCRP Initiative: NIH Countermeasures Against Chemical Threats (CounterACT) Basic Research on Chemical Threats that Affect the Nervous System (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "NIH Countermeasures Against Chemical Threats (CounterACT) Basic Research on Chemical Threats that Affect the Nervous System." This initiative invites applications for basic research projects focused on understanding the mechanisms of toxicity of chemical warfare agents and toxic industrial chemicals that impact the nervous system, with the aim of developing potential therapeutic countermeasures for civilian exposure. The program is particularly significant in enhancing public health responses to chemical threats, emphasizing innovative and transdisciplinary research approaches. Up to four grants totaling $2 million are anticipated for fiscal year 2026, with applications due by 5 PM local time on October 17, 2026. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    CCRP Initiative: NIH Countermeasures Against Chemical Threats (CounterACT) Basic Research on Chemical Threats that Affect the Nervous System (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the CCRP Initiative: NIH Countermeasures Against Chemical Threats (CounterACT) program, focusing on basic research related to chemical warfare agents and toxic industrial chemicals that impact the nervous system. The objective is to elucidate mechanisms of toxicity, identify biological markers, and develop potential therapeutic countermeasures for civilian populations exposed to these chemicals. This funding opportunity is critical for enhancing public safety against chemical threats, with a total of $2 million available for up to four awards, each with a maximum annual budget of $300,000 over three years. Interested applicants must submit their proposals by September 17, 2024, and can direct inquiries to grantsinfo@nih.gov for further information.
    Notice of Intent to Publish a Funding Opportunity Announcement for CCRP Initiative: Countermeasures Against Chemical Threats (CounterACT) Therapeutics Discovery and Early-Stage Development (UG3/UH3 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a Notice of Funding Opportunity (NOFO) for the Countermeasures Against Chemical Threats (CounterACT) initiative, focusing on the early-stage development of therapeutics to address health impacts from toxic chemical exposure. This funding opportunity aims to foster collaborations and innovative projects that can effectively mitigate adverse health effects, with an emphasis on the UG3/UH3 activity code for phased development. The NOFO is anticipated to be released in early 2025, with applications due by October 2025, and awards expected to be made by June 2026, marking a significant investment in public health safety. Interested applicants should prepare to align their proposals with the outlined objectives and timelines.
    CCRP Initiative: Chemical Threat Agent-induced Pulmonary and Ocular Pathophysiological Mechanisms (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) titled "CCRP Initiative: Chemical Threat Agent-induced Pulmonary and Ocular Pathophysiological Mechanisms," aimed at supporting research into the mechanisms of chemical toxicity affecting the lungs and eyes. This initiative seeks to fund projects that explore the health impacts of chemical threat agents, with a focus on identifying molecular and genetic targets for therapeutic countermeasures, utilizing various research methodologies such as animal models and computational modeling. A total of approximately $3 million is available to support up to five grants, with each project eligible for a maximum budget of $300,000 per year over a three-year period. Interested applicants should note that the application period opens on August 24, 2024, with a final submission deadline of September 24, 2026, and can direct inquiries to grantsinfo@nih.gov for further information.
    Limited Competition: CCRP Initiative: Promoting a Basic Understanding of Chemical Threats to Skin (R34 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a limited competition grant opportunity titled "CCRP Initiative: Promoting a Basic Understanding of Chemical Threats to Skin," aimed at funding fundamental research on skin injuries caused by chemical threats recognized as public health risks. The initiative seeks to enhance understanding of the mechanisms leading to chemical-induced skin injuries and to identify potential therapeutic targets for medical countermeasure development, with a focus on examining two or more Chemicals of Concern, including at least one vesicant. This funding opportunity is crucial for advancing knowledge in the field of chemical threat response and wound healing, with an estimated funding amount of $1.25 million available for fiscal year 2025, allowing for up to five awards capped at $225,000 per year. Applications will open on January 16, 2025, and interested parties can direct inquiries to grantsinfo@nih.gov for further information.
    Chemical Countermeasures Research Program (CCRP) Initiative: Basic Research on The Deleterious Effects of Acute Exposure to Ultra-Potent Synthetic (UPS) Opioids (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the Chemical Countermeasures Research Program (CCRP) Initiative, aimed at supporting research on the harmful effects of acute exposure to Ultra-Potent Synthetic (UPS) opioids, such as fentanyl and carfentanil. This initiative seeks to advance understanding of both immediate and delayed health impacts associated with these substances, emphasizing innovative research into toxicity mechanisms and the development of new therapeutic strategies. The program will provide up to four grants, with a maximum award of $300,000 annually over a potential five-year period, totaling an estimated $2 million in funding. Interested applicants, including various educational and nonprofit institutions, must submit their proposals by November 18, 2027, and can direct inquiries to grantsinfo@nih.gov for further information.
    Notice of Intent to Publish a Funding Opportunity Announcement for Limited Competition: Promoting a Basic Understanding of Chemical Threats to Skin (R34 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a Notice of Funding Opportunity (NOFO) aimed at promoting research on skin injuries caused by chemical threats, as part of the Chemical Countermeasures Research Program (CCRP). This initiative, led by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), seeks to investigate the commonalities of such injuries and identify potential therapeutic targets for medical countermeasure development. The NOFO is expected to be published in Fall 2024, with applications due in Winter/Spring 2025, and will offer a funding ceiling of $450,000. Interested applicants should prepare to submit their proposals by the estimated close date of February 16, 2025, with awards anticipated to be made by December 1, 2025.
    Building Partner Capacity to Counter Chemical Weapons Threats
    Active
    Bureau of International Security-Nonproliferation
    The Bureau of International Security-Nonproliferation is offering a funding opportunity titled "Building Partner Capacity to Counter Chemical Weapons Threats," aimed at enhancing global efforts to combat the proliferation of chemical weapons. This initiative seeks to support U.S. and foreign non-profit organizations, educational institutions, and businesses in activities such as research, training, and disrupting the supply chain for chemical precursors, with a focus on reinforcing global norms against chemical weapons use. The total estimated program funding is $30 million, with individual awards ranging from $100,000 to $5 million, and applications are due by January 17, 2025. Interested applicants can reach out to the grantor at csp@state.gov for further information and guidance on the application process.
    Development of Alternative Human Models of Radiation-Induced Injuries (Extracorporeal Systems) (U01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Development of Alternative Human Models of Radiation-Induced Injuries (Extracorporeal Systems)" aimed at supporting research into acute and delayed radiation injuries. This initiative seeks to develop innovative extracorporeal systems that accurately replicate human responses to radiation, facilitating the exploration of injury mechanisms and the testing of medical countermeasures. The funding, structured as a U01 cooperative agreement, has a total budget of $4 million, with plans to award six to eight grants in FY 2026. Interested applicants should note that the submission deadline is February 7, 2025, and they can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Broad Spectrum Products Against Multiple Neurotoxin Botulinum Serotypes (R61/R33 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity aimed at developing broad-spectrum products to counteract Botulinum Neurotoxin (BoNT) intoxication. The initiative seeks to support the creation of therapies that can effectively reverse the effects of BoNT, addressing the limitations of current treatments, which primarily rely on passive immunoglobulin therapy. This funding opportunity utilizes a milestone-driven, biphasic R61/R33 award mechanism, with up to $2.9 million available for 5-6 awards in the R61 phase, focusing on feasibility studies before transitioning to further development in the R33 phase. Interested applicants, including various educational and community organizations, must adhere to NIH's review criteria and submit proposals by May 2, 2025. For more information, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-24-080.html.